News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
TCPCL is the largest and only commercial manufacturer of SDAs for zeolites in India
ICICI Securities expects Hemmo to grow its revenue at a CAGR of 30.0% over FY21E-FY23E
GSKP announced sale of its newly constructed manufacturing plant at Vemgal, Karnataka to Hetero Labs for a cash consideration of Rs1.8bn
Strategic divestment of Ploermel and Edinburgh sites will enable NextPharma to benefit from operational synergies and optimize existing expertise and technologies
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The promoter holding in the company has increased to 37.25%, a rise of 4.9% from 32.35% as of 31 March 2020
India produces 60% of the world’s vaccine
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Zydus has made its brand of Remdesivir, Remdac more affordable at Rs. 899 for a 100 mg lyophilized injection.
Subscribe To Our Newsletter & Stay Updated
